Study Shows Kratom Constituents Inhibit Multiple Liver Drug-Metabolizing Enzymes; Interaction Risk Remains Uncertain

Why it matters

New pharmacokinetic research identifies specific liver enzyme inhibition mechanisms by kratom's active alkaloids, providing critical data for clinicians assessing drug-drug interaction risk in patients combining kratom with medications metabolized by glucuronidation pathways.

The big picture

Researchers at Khon Kaen University investigated how mitragynine and 7-hydroxymitragynine inhibit six human UDP-glucuronosyltransferase (UGT) isoforms responsible for Phase II drug metabolism. Results showed variable inhibition patterns: mitragynine most potently inhibited UGT1A3 (IC50 72 µM), while 7-hydroxymitragynine most strongly inhibited UGT1A9 (IC50 51 µM). However, kinetic analysis revealed that in vivo plasma concentrations of both alkaloids (0.016-0.263 µM) are substantially below the concentrations needed to produce clinically significant inhibition, suggesting herb-drug interaction risk is 'unlikely' but not entirely ruled out.

Key findings

• Mitragynine shows highest inhibition of UGT1A3 (IC50 72 µM)
• 7-Hydroxymitragynine shows strongest inhibition of UGT1A9 (IC50 51 µM)
• Human plasma concentrations (0.016-0.263 µM) are 33-700 times lower than inhibitory concentrations
• Kinetic analysis suggests low probability of clinically significant herb-drug interactions via glucuronidation
• Variable inhibition across different UGT isoforms
• Inhibition mechanisms differ: some competitive, some noncompetitive

What they say

Researchers conclude: 'Although the prediction screening indicated an unlikely potential for herb-drug interaction in humans, further investigation is warranted to comprehensively assess this potential.' They note that 'the experimental Ki values found here are relatively high compared to the maximum plasma concentrations of mitragynine and 7-hydroxymitragynine reported in humans, suggesting an unlikely potential for herb-drug interactions via UGT inhibition.'

Bottom line

**Pharmacokinetic analysis suggests kratom alkaloids are unlikely to cause clinically significant drug interactions via liver glucuronidation inhibition at typical use levels, but variability in dosing and the complexity of polypharmacy warrant continued clinical vigilance.**